Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Produits pharmaceutiques

Marché Fermé - Japan Exchange 08:30:00 01/09/2026			Varia. 5j.	Varia. 1 janv.
5 845,00 ^JPY	+1,39%		+0,83%	+20,89%

01/09	Bourse : Air Liquide vs Elliott, débuts difficiles pour Shein, MediaTek en hausse
01/09	Les marchés veulent éviter le cercle vicieux

Autres langues

31/08	Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House
31/08	Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House
31/08	Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says
31/08	Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
31/08	Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer
31/08	Takeda Pharmaceutical Wins US Approval for New PV Treatment MIMRYLO
29/08	Takeda Pharmaceutical Company Limited Receives U.S. FDA Approval Of MIMRYLO For Treatment Of Erythrocytosis In Adults With Polycythemia Vera
29/08	Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
28/08	US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08	Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition
28/08	Novavax, Inc., Sanofi S.A., And Takeda Pharmaceutical Company Limited Receive Approvals For XFG-Adapted Nuvaxovid Formulation In The U.S., European Union And Japan For 2026-2027 Vaccination Season
28/08	Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)
24/08	FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
24/08	Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1
24/08	Takeda Pharmaceutical Company Limited Receives Approval For Orzeyful (Oveporexton) To Treat Narcolepsy Type 1 In Japan
24/08	Takeda Secures Japan Approval for Orzeyful to Treat Narcolepsy Type 1
24/08	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
20/08	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
18/08	Asian Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $1,523,439, According to a Recent SEC Filing
13/08	Takeda Pharmaceutical Insider Sold Shares Worth $2,828,220, According to a Recent SEC Filing
06/08	Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL
06/08	Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1
06/08	U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1